A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this
2023-11-22 19:51
Eisai Alzheimer Drug Shows Promise in Injected-At-Home Form
An experimental version of Eisai Co.’s Alzheimer’s drug that might be given in patients’ homes exceeded the power
2023-10-26 08:28
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
Merck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech
2023-10-23 13:58
Eisai’s Alzheimer’s Drug Wins Approval in Japan, Following US
Eisai Co.’s breakthrough Alzheimer’s disease drug won clearance from Japanese regulators after the medicine was fully cleared in
2023-09-25 14:26
Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US
Eisai Co.’s breakthrough Alzheimer’s disease drug is poised to gain the backing of Japanese regulators after the medicine
2023-08-21 21:28
Sanofi Was Mystery Bidder That Lost Reata to Biogen
Biogen Inc. narrowly beat out Sanofi SA to clinch its $7.3 billion acquisition of Reata Pharmaceuticals, according to
2023-08-16 03:45
Sage Tumbles as Depression Pill Approval Omits Major Disorder
Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum
2023-08-07 20:18
Women Hold a Third of S&P 500 Boards Seats With Gains in June
Women retained control of a record high one-third of S&P 500 board seats in June as companies moved
2023-07-28 21:56
Biogen to Buy Reata for $7.3 Billion in Rare-Disease Expansion
Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion including debt to expand its rare disease
2023-07-28 19:49
Medicare Proposes Expanding Patient Access to Alzheimer’s Scans
The US Medicare program will roll back rules that limited coverage for an expensive imaging scan for people
2023-07-18 06:25
Lilly Applies for Alzheimer’s Drug’s US Approval After Trial Success
Eli Lilly & Co. said it applied for full US approval of its Alzheimer’s disease drug that’s expected
2023-07-17 22:51
Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program
Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung will retire at the end
2023-07-11 09:56